Research programme: antibacterials - Spero Therapeutics/Roche

Drug Profile

Research programme: antibacterials - Spero Therapeutics/Roche

Alternative Names: MvfR programme - Spero

Latest Information Update: 31 Dec 2015

Price : $50

At a glance

  • Originator Spero Therapeutics
  • Class Antibacterials; Small molecules
  • Mechanism of Action Transcription factor inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Preclinical Gram-negative infections; Pseudomonal infections

Most Recent Events

  • 15 Dec 2015 Spero Therapeutics and Evotec AG agree to co-develop antibacterials for Gram-negative infections
  • 25 Aug 2014 Antimicrobial activity data from preclinical studies in Pseudomonal infections released by Spero Therapeutics
  • 01 Aug 2014 Preclinical trials in Pseudomonal infections in USA (unspecified route)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top